Mr. Speaker, there has been much discussion about the rationale used by Canada's government in deciding on a collaborative approach to hepatitis C assistance. It would be useful to review some of the events of the past to better understand why those years were so significant.
Although an antibody test for hepatitis C was not developed and put into use in the Canadian blood system until 1990, surrogate testing was used in the United States from 1986 to 1990. Since implementation of a specific blood test for hepatitis C in 1990, the Canadian blood system is considered as safe as it can be.
The 1986 to 1990 timeframe is significant and was the rationale for Canada's government to use in offering assistance.
In total, the government has committed approximately $1.4 billion for compensating and assisting people infected with hepatitis C through the blood system. Of this amount, the government already paid $875 million to fulfill our financial obligations to victims under the 1986 to 1990 hepatitis C settlement agreement.
Through this agreement, which was approved by the courts, we have managed to save probably 10 years of litigation. An independent administrator has been named by the courts, a claims process has been put in place, and cheques to claimants are being issued.
As of March 2002, the latest date that figures were reported, the administrator has received and reviewed more than 7,300 claims and more than 5,400 individuals have received over $220 million in compensation benefits. While as of June 2002 there was approximately $900 million in the fund, this is not a surplus. These funds belong to the beneficiaries of the trust. Payment out of this fund may continue for up to 70 years.
In addition, for individuals infected before 1986 and after 1990, the federal government has committed approximately $525 million to provide care. Care is what people need when they are sick.
We have consulted with people across Canada. We have listened and responded by dedicating $15 million for hepatitis C prevention and research, and for establishing community based support programs. We are also spending $125 million for enhanced safety and surveillance of the blood supply.
Another important component of our contribution is an agreement with the provinces and territories to pay half the costs, up to $50 million, to identify and notify all individuals who have been infected with hepatitis C through the blood system so that they can receive the care and treatment that they need. Many of these people are not aware that they are infected and they are not being treated.
As well, we have offered a $300 million transfer to the provinces and territories, of which over $100 million has been transferred to date. This money will ensure that all those who contracted hepatitis C through the blood system will have reasonable and ongoing access to the medical goods and services needed for appropriate treatment and will not incur out of pocket expenses for appropriate hepatitis C care, such as drugs, immunization and nursing care.
Our plan is sensible. It provides the care that people living with hepatitis C need, and it is compassionate.